- Home
- PGY vs PRAX Comparison
PGY vs PRAX Comparison
Compare PGY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- PRAX
- Stock Information
- Founded
- PGY 2016
- PRAX 2015
- Country
- PGY United States
- PRAX United States
- Employees
- PGY N/A
- PRAX N/A
- Industry
- PGY Finance: Consumer Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- PRAX Health Care
- Exchange
- PGY Nasdaq
- PRAX Nasdaq
- Market Cap
- PGY 863.7M
- PRAX 599.7M
- IPO Year
- PGY N/A
- PRAX 2020
- Fundamental
- Price
- PGY $23.25
- PRAX $50.36
- Analyst Decision
- PGY Strong Buy
- PRAX Strong Buy
- Analyst Count
- PGY 9
- PRAX 10
- Target Price
- PGY $23.61
- PRAX $101.00
- AVG Volume (30 Days)
- PGY 2.5M
- PRAX 308.4K
- Earning Date
- PGY 08-07-2025
- PRAX 08-12-2025
- Dividend Yield
- PGY N/A
- PRAX N/A
- EPS Growth
- PGY N/A
- PRAX N/A
- EPS
- PGY N/A
- PRAX N/A
- Revenue
- PGY $1,076,961,000.00
- PRAX $8,122,000.00
- Revenue This Year
- PGY $20.61
- PRAX N/A
- Revenue Next Year
- PGY $13.33
- PRAX $6,358.50
- P/E Ratio
- PGY N/A
- PRAX N/A
- Revenue Growth
- PGY 23.69
- PRAX 270.02
- 52 Week Low
- PGY $8.20
- PRAX $26.70
- 52 Week High
- PGY $23.93
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- PGY 74.41
- PRAX 71.71
- Support Level
- PGY $21.11
- PRAX $45.70
- Resistance Level
- PGY $23.45
- PRAX $53.35
- Average True Range (ATR)
- PGY 1.32
- PRAX 2.51
- MACD
- PGY 0.13
- PRAX 0.55
- Stochastic Oscillator
- PGY 93.40
- PRAX 76.02
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.